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Reactivity of monoclonal antibodies to oncoproteins with normal rat liver,
carcinogen-induced tumours, and premalignant liver lesions
M.J. Embleton and P.C. Butler
Cancer Research Campaign Laboratories, University ofNottingham, University Park, Nottingham NG7 2RD, UK.
Summary Monoclonal antibodies to proteins encoded by the ras, myb, myc, erb-B, src and PDGF-2 genes
were tested for reactivity with normal rat liver, livers from rats fed with 0.06% 2-acetylaminofluorene (AAF),
and premalignant lesions and primary liver tumours from rats given AAF alone or a combined treatment
with diethylnitrosamine and AAF. Radioimmunoassays were performed with plasma membrane fractions and
total soluble subcellular extracts of the tissues, and immunoperoxidase staining was carried out on frozen
tissue sections. All of the antibodies were positive in radioimmunoassays, some more strongly than others,
and each antibody bound equally to extracts of different kinds of tissue. Immunohistology revealed significant
staining of normal liver by 5 of the 6 antibodies, and only minor qualitative differences of the staining pattern
in some tumours and hyperplastic nodules. It was concluded that these antibodies were not able to
discriminate sufficiently well between normal, premalignant and malignant rat liver to be of value in
identifying the precursor cells of malignant tumours.
Monoclonal antibodies raised against protein products
encoded by cellular oncogenes are currently undergoing
widespread evaluation of their reactivity with normal,
neoplastic and preneoplastic tissues with a view to
establishing criteria of diagnostic or prognostic value.
Most studies so far reported have involved immunohistology
on human tissue sections, and some have used flow
cytometry (Horan-Hand et al., 1984; Thor et al., 1984;
Williams et al., 1985; Kerr et al., 1985; Evan et al., 1985;
Ghosh et al., 1986; Watson et al., 1986; Hendy-Ibbs et al.,
1987; Furth et al., 1987). There has been some inconsistency
between different reports, but there is a general feeling that
anti-oncoprotein antibodies can potentially distinguish
between malignant and non-malignant human cells by
detecting altered protein expression.
The purpose of the present study was to determine the
reactivity of a panel of such monoclonal antibodies with
normal, pre-malignant and malignant liver tissues derived
from an experimental rat model in which a variety of
identifiable lesions are induced in response to carcinogen
treatment. The premalignant lesions ultimately giving rise to
malignant tumours in rat liver are still a subject of contro-
versy, several candidate cell types having been proposed
(Yaswen et al., 1985; Potter, 1978), and the study was
undertaken in order to address this problem. Nucleic acid
hybridisation techniques have indicated increased expression
of c-ras and c-myc oncogenes in neoplastic and carcinogen-
modified cells in the livers of rats treated with hepato-
carcinogens (Makino et al., 1984; Corcos et al., 1984;
Yaswen et al., 1985) and it therefore seemed possible that
antibodies recognising oncogene products might, by showing
increased reactivity with cells expressing activated oncogenes,
be of value in identifying cell types undergoing malignant
change.
Materials and methods
Animals
Male Fischer F344 rats were purchased at 8 to 10 weeks of
age from Olac Ltd. (Bicester, Oxon, UK). They were housed
on sawdust in polyethylene cages, and were fed Oxoid
Breeding Diet ( H.C. Styles, Bewdley, UK) and tap water ad
libitum other than when treated with carcinogen diet.
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Carcinogen treatment
Rats were treated with one of two protocols:
(a) A modification of a procedure described by Teebor
and Becker (1971) in which they were fed with 0.06% w/w 2-
acetylaminofluorene (AAF; Aldrich Chemical Co. Ltd.,
Gillingham, UK) in ground Oxoid diet for cycles of two
weeks. Four cycles were administered, with one week on
standard diet between each.
(b) Intraperitoneal injection of diethylnitrosamine (DENA;
Sigma Chemical Co. Ltd., Poole) at 200mgkg-1 body wt,
followed two weeks later by oral 0.02% w/w AAF for two
weeks, with a hepatotoxic dose of carbon tetrachloride in
corn oil (0.5ml 1:1 mixture) by gastric intubation after the
first week of AAF diet (Solt & Farber, 1976).
Antibodies
Murine monoclonal antibodies as detailed below were
obtained through the courtesy of Mr N.A. Habib, University
Dept. of Surgery, Bristol Royal Infirmary, Bristol, UK:
Anti-myc Antibody 6E10 (Evan et al., 1985) was donated
by Prof. K. Sikora, Royal Postgraduate Medical School,
London. This antibody, which recognises p62" was
supplied in purified form.
Anti-ras Antibody 96-118 was supplied in ascites form by
Dr H.L. Niman, Scripps Clinic and Research Foundation,
La Jolla, CA, USA (SCRF). It was raised against a synthetic
peptide comprising part of the v-Ha-ras sequence, and
recognises p2l"'.
Anti-myb Antibody 133-10F6 was supplied as freeze-
dried ascites by the NCI Repository, Bethesda, MD, USA. It
was raised against a peptide comprising residues 160-175 of
the predicted sequence for v-myb of AMV, and recognises
proteins of Mr-45 and 75kD.
Anti-src Antibody 202-1108 came as freeze-dried ascites
from the NCI Repository. It was raised against a peptide
corresponding to residues 273-284 of the predicted v-src
sequence, and recognises proteins of 55, 60, 70 and 140 kD.
Anti-erb-B Antibody 173-lcl 1 was supplied by the NCI
Repository as freeze-dried ascites. It was raised against a
peptide corresponding to residues 23-29 of the erb-B
sequence, and recognises a principal protein of 120 kD, as
well as minor 35 and 7OkD proteins.
Anti-PDGF-2 Antibody 18-9B10 was supplied as freeze-
dried ascites by the NCI Repository. It was raised against a
synthetic peptide corresponding to residues 1-18 of the
PDGF-2 sequence, and recognises a 56 kD protein.
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Anti-mivh, anti-src, anti-erb-B and anti-PDGF-2, from the
NCI Repository, were originally prepared at SCRF. All were
IgGs. Reactions of the SCRF monoclonal antibodies are
blocked specifically by the relevant synthetic peptide,
according to the suppliers.
All antibodies were stored at -70'C in small aliquots and
diluted in phosphate-buffered saline (PBS, pH 7.2) before
use. As a negative control an IgG2b monoclonal antibody
raised against a human osteogenic sarcoma cell line, 791T/36
(Embleton et al., 1981), was used. This antibody does not
react with normal rat liver or rat liver tumours.
Tissue extracts
Liver from normal rats or rats fed with 0.06% AAF, and
excised liver tumours arising in the latter were processed into
a crude total subcellular (soluble) extract and a plasma
membrane-enriched fraction. The soluble extract was
prepared by homogenising fresh tissue in 5vol of 1% NP40
(BDH Chemicals Co. Ltd., Poole, UK) in distilled water,
using an Ultra-turrax homogeniser at about half maximum
output. The homogenate was sonicated, centrifuged at
40,000g for 30min, and the supernatant was dialysed
overnight against PBS (pH 7.2), to remove the detergent.
Plasma membrane was prepared by homogenising fresh
tissue in 5 vol of a buffer consisting of NaHCO3 (10-3 M),
CaCl2 (2 x 10- 3 M) and MgCl2 ((2 x 10- 3 M) and centrifuging
the homogenate at 40,000g over a layer of 37% w/v sucrose
solution for 60min. The band of membranous material at
the interface between the buffer and the sucrose was taken
and diluted with fresh buffer, and concentrated by a further
centrifugation at 40,000g for 60min. The pellet was
suspended in PBS and sonicated. The protein concentrations
of all extracts were estimated by the method of Lowry et al.
(1951) and aliquots containing 0.02% sodium azide were
stored at -70 C.
Radioimmunoassays
Rabbit Ig anti-mouse Ig (Dako, Copenhagen, Denmark) was
labelled with 1251 using a chloramine T method described by
Brown et al. (1980). Anti-p3lras antibody was purified using
Sepharose-protein A, and 1251-labelled by the same
procedure.
Tissue extracts were adjusted to 200,ugml - protein
concentration by dilution in PBS containing 10 -3 M MgCl2
and added to LUX 60-well HL-A plates (Flow Laboratories,
Rickmansworth, UK) at 10lp per well. The plates were
incubated overnight at 4°C and washed 3 times in PBS
containing 10 3 M MgCl2, 0.1% rabbit serum, and 0.1%
bovine serum albumin (referred to hereafter as 'washing
buffer'). The wells were then 'blocked' by incubating for 1 to
2 h at 200C with 10p1 washing buffer per well containing 2%
bovine serum albumin. The plates were again washed 3 times
and antibody in the form of ascites (or purified in the case
of anti-p62rYc) was added at 10jil/well diluted as indicated in
the text, followed by 1 h incubation at 20"C. Control wells
were routinely treated with the washing buffer at this stage,
and additional controls treated with anti-human osteogenic
sarcoma antibody 791T/36 ascites were used. The plates were
again washed 3 times and Io,il of 1251-anti-mouse Ig giving
3 x 104cpm was added to each well. Following a further
incubation for 1 h at 20°C, the plates were washed 3 times,
dried down and the wells sealed with a plastic spray film
(Nobecutane, Astra Pharmaceuticals, Kings Langley, UK).
The wells were separated and counted in a gamma counter.
Results were expressed as the increment of cpm obtained in
antibody-treated wells over that in buffer-treated wells, after
subtracting any counts bound non-specifically to blocked
wells not pretreated with antigen but subsequently treated
with antibody.
In one experiment total soluble extracts were treated with
1251-labelled anti-ras antibody (3 x 104cpm per well). In this
case the i25I-labelled antibody was used in place of
unlabelled antibody and the anti-mouse Ig step was omitted.
Immunohistology
Samples of normal and carcinogen-treated liver and primary
tumours were mounted on thin cork blocks in Tissue-Tek
OCT embedding compound (Raymond A. Lamb, London,
UK) and frozen in isopentane cooled with liquid nitrogen.
Hyperplastic nodules recognisable as small greyish surface
nodules were separately excised from the livers of rats
exposed to the DENA/AAF protocol, and mounted and
frozen in the same way. When frozen, all specimens were
stored at -70°C. Cryostat sections were cut at 5pm
thickness and mounted on gelatin-coated slides. After rapid
thawing each section was fixed for 15min in ice-cold
acetone.
Ascites antibodies were diluted to 10-2 or 10-3 in PBS,
and anti-myc was used at 2 ugml-1. Immunoperoxidase
staining was carried out as described by Holmes et al.
(1982), using a cascade of reagents consisting of the
monoclonal antibody, rabbit anti-mouse Ig (1/1,000), swine
anti-rabbit Ig (1/40), and peroxidase-rabbit antiperoxidase
complex (1/80) (Dako, Copenhagen, Denmark), followed by
diaminobenzidine (DAB) and hydrogen peroxide (5mg DAB
in 10ml Tris-saline, pH7.6, containing 0.01% H202).
Sections were washed with Tris-saline between each reagent,
and reagents were incubated for 30min at room temperature
except during the final step with DAB and H202. which
involved a 5 min incubation at 37°C. Slides were counter-
stained with Mayer's haemalum, dehydrated in alcohol,
cleared in xylene and mounted in DPX (BDH Chemicals
Ltd., Poole, UK). Control sections were treated with anti-
human tumour monoclonal antibody 791T/36 (Embleton et
al., 1981) in place of the anti-oncoprotein antibodies.
Results
Liver lesions
The AAF diet based on Teebor and Becker (1971) gave rise
to cirrhosis, small groups of proliferating oval cells and foci
of cells exhibiting raised levels of gamma-glutamyl trans-
peptidase (James & Embleton, 1986). Primary liver tumours
(hepatocellular carcinomas and cholangiocarcinomas) began
to appear approximately one year after commencing the diet.
The Solt and Farber (1976) protocol produced similar early
lesions and also numerous greyish hyperplastic nodules at
the liver surface within 2 months of commencing the
treatment. Primary tumours developed from 7 months
onwards.
Radioimmunoassay
Total soluble and plasmcl membrane extracts were tested by
radioimmunoassay initially_with ascites fluids diluted 1/500
and anti-myc antibody at 2 lig ml- 1. The results are shown in
Figure 1. The highest activity was seen with anti-ras
antibody, but it is not possible to draw firm conclusions
about the relative concentrations of the different onco-
proteins in a given tissue extract because the antibody
content of the ascites fluid was not precisely known, or the
affinities of the antibodies. The principal finding in this
experiment was that there was no significant difference in
binding of any of the antibodies to extracts of normal liver,
liver from AAF-treated rats, or primary AAF-induced liver
tumours. With most antibodies the binding to total soluble
material and plasma membrane was similar but anti-myb
bound more to total extract (which contained nuclear com-
ponents) than to plasma membrane; however, bound cpm
were low even with the total soluble extract. Monoclonal
antibody 791T/36 gave negligible binding to either tumour or
normal extracts. Similar assays were carried out with total
soluble extracts of three transplanted hepatomas originally
induced with 4-dimethylaminoazobenzene in comparison
with two primary AAF-induced hepatomas (Figure 2). No
consistent differences were seen in binding of anti-ras, anti-50 M.J. EMBLETON & P.C. BUTLER
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Figure 1 Reactions of anti-oncoprotein monoclonal antibodies with normal liver, AAF-treated liver and primary liver tumour
extracts, by radioimmunoassay.
Total soluble extracts and plasma membrane extracts (see Materials and methods) were used as antigen at a concentration of
200pgml-1 protein. Ascites monoclonal antibodies were diluted 1/500, and anti-myc was used at 2pgml-'. Binding was detected
using 125I-labelled anti-mouse Ig.
2AF5a, 2AF5b, 2AF6b and 2AF7 were primary AAF-induced liver tumours. 'AAF diet' refers to liver from animals taken mid-
way in their fourth cycle of 0.06% AAF diet. 'Post-diet' refers to liver from rats which had completed 4 cycles of AAF diet 3
months previously. * plasma membrane; O total extract.
myc or anti-PGDF-2 to extracts of either transplanted or
primary tumours, although one primary tumour extract
(2AF7) failed to bind anti-myb; this extract also gave no
more than marginal reactivity with anti-myb in Figure 1.
Titrations of each antibody were performed against each
of the total soluble extracts shown in Figure 1, using
dilutions of ascites from 10-2 to 10-6 and anti-myc from
20pgml 1 to 2ngml- 1 Most of the ascites preparations
showed high non-specific binding to blocked plates not
pretreated with antigen at 10-2 dilution, but this
disappeared at 10-3. Virtually every antibody-antigen
combination showed similar titration curves, a few
representative examples of which are shown in Figure 3,
depicting the titration of anti-ras and anti-src against normal
rat liver and two primary tumour extracts. At 10-2 dilution
antigen binding appeared suboptimal, perhaps due in part to
a prozone effect due to antibody excess, and undoubtedly
influenced by the high level of non-specific binding. From
the peak at 10-3 dilution, binding titrated out at 10-5 in all
cases. Anti-myc titrated out progressively from 20upgml-I to
20ngml 1 (data not shown). These titrations failed to reveal
any significant differences between normal liver, carcinogen-
treated liver or tumour extracts at any antibody
concentration.
Finally, 125I-labelled anti-ras was tested against tissue
extracts in a direct assay. Total extract and plasma
membrane produced similar results (Figure 4). Binding to
normal liver and AAF-treated liver extracts was at least
equal to that in specimens from four primary tumours. The
specificity of the 1251-anti-)ras antibody was confirimed by
showing that binding to fixed cells of a p2Iras expressing cell
line could be inhibited by 5-fold excess unlabelled anti-ras,
but not by 5-fold excess anti-myc; conversely 125I-anti-myc
was blocked by 'cold' anti-myc but not by 'cold' anti-ras.
These data are reported elsewhere (Embleton et al., 1986).
Immunohistology
Liver The staining pattern of each antibody in normal liver
is indicated in Table I and illustrated in Figure 5(a)-(e). All
the antibodies except anti-src produced peroxidase staining
of hepatocytes, which although generally of no more than
moderate intensity, was clearly visible. In some cases other
cells within the liver (e.g. portal tracts) were also stained.
Anti-src produced equivocal results, and was not clearly
positive. Livers from AAF-treated rats, either still on the
diet or three months post-treatment, showed similar staining
patterns although there were structural alterations such as
mild cirrhosis and isolated areas of oval cell proliferation.
Hepatocytes exhibited the normal staining pattern as
summarised in Table I, and cirrhotic connective tissue had
the same staining characteristics as indicated for portal tracts
in normal liver. Oval cells showed no clear affinity for any
of the antibodies. Anti-ostegenic sarcoma antibody 791T/36
was completely negative for all tissues.
The staining of nuclei by anti-myc agrees with other
reports (Sikora et al., 1985; Watson et al., 1986; Hendy-Ibbs
et al., 1987). However, it is surprising that this pattern wasONCOPROTEINS IN RAT LIVER CARCINOGENESIS
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Figure 2 Reactions of anti-oncoprotein monoclonal antibodies
with soluble extracts ofprimary and transplanted rat liver tumours,
by radioimmunoassay.
Total soluble extracts were used at 200pgml - i protein
concentration. Ascites antibodies were used at 1/1,000 dilution
and anti-myc at 2,gml-. D23, D192A and D261 were
transplanted rat hepatomas originally induced by oral 4-
dimethylaminoazobenzene. 2AF5B and 2AF7 were primary
AAF-induced tumours.
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Figure 3 Titration ofanti-oncoprotein monoclonal antibodies with
soluble extracts ofnormal rat liver tumours, by radioimmunoassay.
Total soluble tissue extracts were used at 200 pgml. ' protein
concentration. Antibodies to the other oncoproteins produced
similar titration profiles, although with different peak values.
Other tissue extracts gave similar results to those of liver and
tumours 2AF5a and 2AF6b. * * anti-ras; -anti-
src.
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Figure 4 Binding of 125I-labelled anti-ras monoclonal antibody to
normal and AAF-treated rat liver and primary liver tumour
extracts.
Tissue extracts were used at 200pgml ' protein concentration.
'AAF diet' refers to liver from animals mid-way through a
fourth cycle of 0.06% AAF diet. 2AF5a, 2AF5b, 2AF6 and
2AF7 were primary AAF-induced liver tumours. * Plasma
membrane; C] total extract.
Table I Immunoperoxidase staining reactions of anti-oncoprotein
monoclonal antibodies with normal rat liver
Antibody Pattern ofstaining
anti-ras Moderate staining of hepatocyte plasma membrane,
particularly in membrane adjacent to sinusoids.
Portal tracts uniformly positive.
anti-PDGF-2 Punctuate, granular staining evenly distributed in the
hepatocyte cytoplasms and membrane. Portal tracts
negative.
anti-src Equivocal staining of hepatocyte plasma membrane;
negative or very weak. Portal tracts negative.
anti-erb-B Moderate staining ofhepatocyte cytoplasm and
portal tracts.
anti-myb Moderate staining of hepatocyte plasma membrane
and cytoplasm, but non-uniform in distribution.
Nuclei stained in some cells, but not all. Portal tracts
uniformly positive.
anti-myc Hepatocyte nuclei positively stained. Moderate
staining of cytoplasm adjacent to plasma membrane
in some hepatocytes. Portal tracts uniformly stained.
not consistcntly obscrved with anti-rn vb, since nlvh onco-
protein is also located in nuclei (Bishop, 1983; Heldin &
Westermark, 1984). Moreover, anti-myb had bound to total
soluble tissue extracts containing nuclear material more
strongly than to plasma membrane. but anti-myc did not
discriminate between the two types of extract (Figure 1).
Nodules and tumours Hyperplastic nodules and tumours
mostly showed little deviation in the staining pattern of their
constituent cells from that of normal liver tissue, apart from
increased heterogeneity. That is, there was a tendency for
variable intensity of staining within a given section, which
was not apparent in normal or AAF-treated liver, but the
structures stained were usually the same. There were a few
exceptions however; one nodule (designated NI) showed a
loss of staining by anti-PDGF-2 antibody such that only
small isolated groups of cells had the punctate staining
characteristic of normal hepatocytes, most of the cells being
negative (Figure 5(f)). Another nodule (N2) contained cells
which displayed moderate cytoplasmic staining by anti-src
(Figure 5(g)) and cells which stained in the cytoplasm rather
than the plasma membrane with anti-ras (Figure 5(h)). In the
case of both antibodies, staining was heterogeneous and
there were negative areas. One tumour with mixed elements
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Figure 5 Immunoperoxidase staining of normal liver and carcinogen-induced hepatic nodules by anti-oncoprotein monoclonal
antibodies.
(a) Normal liver stained with anti-myc. Nuclei are prominent due to deposition of brown pigment, some of which is
concentrated into granules within the nuclei ( x 500). (b) Normal liver stained with anti-PDGF-2. Staining of all hepatocytes has a
granular, punctate appearance ( x 500). (c) Normal liver stained with anti-src. No dark staining visible; background staining by
Mayer's haemalum only (x 500). (d) Normal liver stained with anti-ras. Dark stain visible on plasma membranes adjacent to
sinusoids (x 500). (e) Normal liver stained with anti-mb. Generalised weak staining, with areas of darker staining on plasma
membrane adjacent to sinusoids. Some nuclei stained, but others unstained (x 500). (f) Nodule NI stained with anti-PDGF-2.
Most of the cells are negative, with isolated foci of normally stained cells; compare with (b) ( x 500). (g) Nodule N2 stained with
anti-src. Generalised cytoplasmic staining; contrast with (c) ( x 500). (h) Nodule N2 stained with anti-ras. Heterogeneous staining,
with areas of cells showing uniform cytoplasmic stain rather than plasma membrane localisation; compare with (d) ( x 500).
of hepatocellular carcinoma and cholangiocarcinoma
(induced by the combined DENA and AAF protocol and
designated DA5) showed weak uniform cytoplasmic staining
with anti-m.hb, similar to that observed in normal portal
tracts and in cirrhotic connective tissue in carcinogen-treated
liver. these examples were the only clear differences observed
in comparison with staining of normal liver.
Discussion
Previous reports in which rats exposed to hepatocarcinogen
protocols have been have been examined have indicated
elevated levels of c-ras and c-myc expression in liver tumours
and putatively premalignant cells. In rats fed 3'-methyl-4-
dimethylaminoazobenzene, Makino et al. (1984)
demonstrated elevated c-Ha-ras expression in primary
tumours and also in non-tumorous parts of the liver, and
elevated c-myc in tumours only. It was suggested that raised
c-Ha-ras was related to hepatocyte proliferation and c-myc
was associated with oncogenesis. In a study using three
doses of DENA given after two-thirds hepatectomy, Corcos
et al. (1984) reported raised levels of c-Ki-ras, c-Ha-ras and
c-myc in both primary tumours and surrounding liver cells.
Yaswen et al. (1985) have examined the expression of six
oncogenes in rats fed 0.1% ethionine in a choline-deficient
diet. They found that c-Ki-ras, c-Ha-ras and c-myc
expression in the liver increased 2 weeks after starting the
diet. The highest levels of c-myc and c-Ki-ras were found in
oval cells, while c-Ha-ras was present in greater
concentration in hepatocytes than in oval cells. A primary
tumour was found to contain high levels of c-Ki-ras and c-
myc. The c-src gene was expressed in the liver in detectableONCOPROTEINS IN RAT LIVER CARCINOGENESIS 53
quantities but showed no gross clhaniges during
carcinogenesis, and c-abl and c-mos were undetectable. In all
these studies oncogene expression was detected by hybrid-
isation of extracted RNA in northern blots with labelled
DNA probes.
The detection of oncoproteins by monoclonal antibody
binding in our experiments did not yield comparable
differences between normal liver, carcinogen-treated liver,
lesions considered to be premalignant (oval cells and
nodules) and primary liver tumours. Five of the six
antibodies tested stained normal liver sections, and all six
bound to normal liver extracts to a greater or lesser extent.
Thus the oncoproteins can be considered to have been
present in normal liver. Although the assays used were not
strictly quantitative, increased binding or increased staining
intensity should certainly have been observed within any
single experiment had carcinogen-treated liver, nodules or
tumours processed oncoprotein concentrations significantly
above those of normal liver. That no such elevated binding
was seen suggests that these tissues did not contain grossly
increased amounts of oncoproteins. These findings are
consistent with several reports in the literature showing that
both normal and malignant cells and tissues stain with
comparable intensity with anti-oncoprotein monoclonal anti-
bodies (Kerr et al., 1985; Sikora et al., 1985; Williams et al.,
1985; Furth et al., 1987; Ghosh et al., 1986; Embleton et al.,
1986). Such observations confirm the view that oncogenes
are probably very important in regulating normal cell growth
and function. In some cases tumour and nodule sections
showed some morphological difference in staining pattern,
the principal characteristic being increased heterogeneity, and
again this is commonly observed with human tumour
specimens. It is doubtful if such differences are pronounced
enough or consistent enough to be of diagnostic significance;
certainly in our studies they could not be considered of
sufficient reliability to identify the premalignant precursors
of truly malignant cells.
The apparent lack of correlation between detection of
oncogene-associated RNA by hybridisation and the protein
products of the genes in rat liver carcinogenesis systems
needs further investigation. The discrepancy may be a real
one in that an RNA message is not necessarily transcribed
into protein, or it may simply be a reflection of the different
technologies used. One possible factor is the different
carcinogen protocols, but Farber (1956) has drawn attention
to the close similarities in the histological changes induced
by ethionine, 3'-methyl-4-dimethylaminoazobenzene and
AAF, so this seems unlikely to be cause for any major
disagreement. Perhaps a fruitful area of research would be to
determine tissue or cellular concentrations of oncoproteins
by biochemical means not involving antibodies, and to
compare these concentrations with the results of antibody
binding or staining assays. Whatever the outcome of such
investigations, the conclusions to be drawn from the
experiments described in this paper are that currently
available monoclonal antibodies to oncogene products do
not consistently distinguish between normal rat liver, liver
from carcinogen-treated rats, tumours or preneoplastic
lesions, and that therefore they cannot be used reliably to
define the precursor cells of malignant tumours.
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